Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $43.70. The company's market cap stands at 17.22B, with a P/E ratio of -5.47.
On 2026-02-01, Moderna(MRNA) stock traded between a low of $43.43 and a high of $46.68. Shares are currently priced at $43.70, which is +0.6% above the low and -6.4% below the high.
Moderna(MRNA) shares are trading with a volume of 10.96M, against a daily average of 16.02M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
MRNA News
Moderna (NasdaqGS:MRNA) announced a global collaboration and license agreement with Recordati to develop and commercialize its investigational mRNA therapy, mRN...
Moderna ( (MRNA) ) has fallen by -8.17%. Read on to learn why. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smar...
Moderna has announced a collaboration and license agreement with Recordati to advance mRNA-3927 for propionic acidemia, with Moderna leading development and man...
Analyst ratings
74%
of 27 ratingsMore MRNA News
Moderna (MRNA) announced on Friday that the company’s chief medical officer, Jacqueline Miller, will resign effective Mar. 2, a little over a year after taking...
Moderna (MRNA) “announced a strategic collaboration with Recordati to advance Moderna’s investigational propionic acidemia therapeutic, mRNA-3927, through the f...
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Moderna (MRNA) to $40 from $25 and keeps a Hold rating on the shares. The firm updated its mo...
Moderna (NasdaqGS:MRNA) plans to stop funding new Phase III vaccine trials in the U.S., citing a more hostile vaccine climate. The company aims to secure exter...
Barclays analyst Eliana Merle assumed coverage of Moderna (MRNA) with an Equal Weight rating and $25 price target Barclays initiated coverage of 12 biotech stoc...
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview This Phase 3 study, officially titled “A Ph...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.